EGLN inhibitor protects normal tissue and enables RT in mouse model of pancreatic cancer

(American Association for Cancer Research) Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival in a mouse model of unresectable pancreatic cancer.